Title: 2017 ACVIM Forum Research Abstract Program Document date: 2017_6_15
ID: ri2w5iby_339
Snippet: In conclusion, this study identified differences in the fecal microbiota as well as fecal lactate and bile acid concentrations between dogs with EPI and healthy control dogs. CD25, also known as interleukin-2 receptor a (IL-2Ra), is a 55 kDa transmembrane cytokine receptor, primarily expressed by activated T cells, regulatory T cells (Tregs), and some types of cancer cells. In humans, increased expression of membrane-bound CD25 has been reported .....
Document: In conclusion, this study identified differences in the fecal microbiota as well as fecal lactate and bile acid concentrations between dogs with EPI and healthy control dogs. CD25, also known as interleukin-2 receptor a (IL-2Ra), is a 55 kDa transmembrane cytokine receptor, primarily expressed by activated T cells, regulatory T cells (Tregs), and some types of cancer cells. In humans, increased expression of membrane-bound CD25 has been reported in patients with autoimmune or inflammatory diseases, during transplant rejection, and some types of neoplasia. A soluble form of CD25 (sCD25) is generated by proteolytic cleavage and has a molecular mass of 45 kDa. Elevated serum concentrations of sCD25 have been reported in human patients with the aforementioned conditions. A positive correlation has been reported between the membrane expression of CD25 and the serum concentration of sCD25. In vitro, activated T cells and Tregs have been shown to shed sCD25, therefore high concentrations of serum sCD25 are thought to be reflective of a sustained immune activation. Moreover, sCD25 has been used as a biomarker to help characterize disease progression, prognosis, and treatment in humans. Thus, the aim of this study was to establish and analytically validate a radioimmunoassay for the measurement of sCD25 in canine serum.
Search related documents:
Co phrase search for related documents- sCD25 biomarker and soluble form: 1
- serum concentration and study aim: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43
- serum concentration and transplant rejection: 1
- serum concentration and treatment prognosis: 1, 2, 3
- serum sCD25 and soluble form: 1
- soluble form and study aim: 1, 2, 3
- study aim and transplant rejection: 1, 2, 3
- study aim and treatment prognosis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35
- study aim and treatment prognosis disease progression: 1
- transplant rejection and treatment prognosis: 1
Co phrase search for related documents, hyperlinks ordered by date